

Rahul Bhattacharya

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3001985/publications.pdf>

Version: 2024-02-01

16
papers

390
citations

759233

12
h-index

940533

16
g-index

16
all docs

16
docs citations

16
times ranked

435
citing authors

#	ARTICLE	IF	CITATIONS
1	Glycoengineering Human Neural and Adipose Stem Cells with Novel Thiol-Modified N-Acetylmannosamine (ManNAc) Analogs. <i>Cells</i> , 2021, 10, 377.	4.1	11
2	Comparison of Three Glycoproteomic Methods for the Analysis of the Secretome of CHO Cells Treated with 1,3,4-O-Bu ₃ ManNAc. <i>Bioengineering</i> , 2020, 7, 144.	3.5	4
3	Combining Butyrate ManNAc with Glycoengineered CHO Cells Improves EPO Glycan Quality and Production. <i>Biotechnology Journal</i> , 2019, 14, 1800186.	3.5	23
4	Butyrate ManNAc analog improves protein expression in Chinese hamster ovary cells. <i>Biotechnology and Bioengineering</i> , 2018, 115, 1531-1541.	3.3	24
5	Pharmacological, Physicochemical, and Drug-Relevant Biological Properties of Short Chain Fatty Acid Hexosamine Analogues Used in Metabolic Glycoengineering. <i>Molecular Pharmaceutics</i> , 2018, 15, 705-720.	4.6	9
6	Glycoengineering of Esterase Activity through Metabolic Flux-Based Modulation of Sialic Acid. <i>ChemBioChem</i> , 2017, 18, 1204-1215.	2.6	14
7	A novel sugar analog enhances sialic acid production and biotherapeutic sialylation in CHO cells. <i>Biotechnology and Bioengineering</i> , 2017, 114, 1899-1902.	3.3	32
8	Electrospun Microfiber Scaffolds with Anti-Inflammatory Tributanoylated N-Acetyl-D-Glucosamine Promote Cartilage Regeneration. <i>Tissue Engineering - Part A</i> , 2016, 22, 689-697.	3.1	19
9	Local delivery of a carbohydrate analog for reducing arthritic inflammation and rebuilding cartilage. <i>Biomaterials</i> , 2016, 83, 93-101.	11.4	22
10	Metabolic flux-driven sialylation alters internalization, recycling, and drug sensitivity of the epidermal growth factor receptor (EGFR) in SW1990 pancreatic cancer cells. <i>Oncotarget</i> , 2016, 7, 66491-66511.	1.8	35
11	Identification of sialylated glycoproteins from metabolically oligosaccharide engineered pancreatic cells. <i>Clinical Proteomics</i> , 2015, 12, 11.	2.1	33
12	Metabolic glycoengineering sensitizes drug-resistant pancreatic cancer cells to tyrosine kinase inhibitors erlotinib and gefitinib. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 1223-1227.	2.2	33
13	Short-Chain Fatty Acid-Modified Hexosamine for Tissue-Engineering Osteoarthritic Cartilage. <i>Tissue Engineering - Part A</i> , 2013, 19, 2035-2044.	3.1	13
14	Differential Response of Chondrocytes and Chondrogenic-Induced Mesenchymal Stem Cells to C1-OH Tributanoylated N-Acetylhexosamines. <i>PLoS ONE</i> , 2013, 8, e58899.	2.5	12
15	Extracellular and intracellular esterase processing of SCFA hexosamine analogs: Implications for metabolic glycoengineering and drug delivery. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 6929-6933.	2.2	37
16	Metabolic oligosaccharide engineering with N-acyl functionalized ManNAc analogs: Cytotoxicity, metabolic flux, and glycan considerations. <i>Biotechnology and Bioengineering</i> , 2012, 109, 992-1006.	3.3	69